{"product_id":"passagebio-business-model-canvas","title":"Passage Bio Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio Business Model Canvas: Gene Therapy Strategy, Partnerships \u0026amp; Commercial Playbook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover Passage Bio’s strategic playbook with our concise Business Model Canvas—uncover how targeted gene therapies, strategic partnerships, and payer-focused commercialization drive value and growth; download the full Word\/Excel canvas for a section-by-section breakdown, financial implications, and actionable insights to inform investments, benchmarking, or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUniversity of Pennsylvania Gene Therapy Program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe University of Pennsylvania Gene Therapy Program collaboration, led by Dr. James Wilson, gives Passage Bio access to AAV (adeno-associated virus) platforms and IP that accelerated its pipeline; as of Dec 31, 2025 Passage Bio reported R\u0026amp;D partnerships contributing to 38% of preclinical program funding and reduced early-stage spend by an estimated $24M through shared trials and licensing terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio uses specialized contract manufacturing organizations (CMOs) to produce AAV viral vectors for clinical programs, with partners scaling from lab to cGMP batches to meet FDA standards; in 2024 CMOs handled \u0026gt;90% of vector production industry-wide and reduce capital spend by millions. Maintaining CMO ties secures trial supplies and will be critical for global commercial supply-chain stability as Passage Bio advances toward late-stage studies and potential 2026+ launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWorking with groups like the Association for Frontotemporal Degeneration helps Passage Bio refine patient needs and cut recruitment time—FTD advocacy networks supported ~40% of patients in recent U.S. rare‑disease trial enrollments, crucial when eligible pools number in the low hundreds. These partners shape endpoints, boost community trust, and strengthen value claims to payers and investors by aligning trials with real‑world patient priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio partners with global clinical research organizations (CROs) to run multi-center gene therapy trials, outsourcing site monitoring, data collection, and regional regulatory compliance so the company stays lean while ensuring trial quality.\u003c\/p\u003e\n\u003cp\u003eUsing CROs lets Passage Bio scale across programs—by end-2024 CRO-managed trials supported ~40 sites across 10 countries, cutting internal clinical headcount and saving an estimated $6–9M per Phase 2 program.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCROs manage site monitoring, data capture, regulatory filings\u003c\/li\u003e\n\u003cli\u003eSupports ~40 sites in 10 countries (end-2024)\u003c\/li\u003e\n\u003cli\u003eSaves ~$6–9M per Phase 2 program via outsourcing\u003c\/li\u003e\n\u003cli\u003eEnables simultaneous programs at different stages\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContinuous engagement with the FDA and EMA is essential for Passage Bio to secure orphan drug designations and fast-track status—both granted to multiple gene therapies industry-wide (FDA awarded ~100 orphan approvals in 2024)—accelerating CNS program timelines and lowering trial costs.\u003c\/p\u003e\n\u003cp\u003eCollaborative regulator ties reduce trial-design and safety risks; successful approvals remain the primary gatekeeper to commercializing Passage Bio’s gene therapies, impacting peak revenue projections tied to launch timing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOrphan\/fast-track pursuit: shortens approval time, cuts development cost\u003c\/li\u003e\n\u003cli\u003eRegulatory collaboration: lowers safety\/trial redesign risk\u003c\/li\u003e\n\u003cli\u003eApproval gating: controls commercialization and revenue timing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio partners cut $24M R\u0026amp;D, outsource \u0026gt;90% production, and drive 40% patient recruitment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio’s key partnerships (UPenn GTP, CMOs, CROs, patient groups, regulators) cut early R\u0026amp;D spend ~$24M, supported \u0026gt;90% outsourced vector production, enabled ~40 trial sites in 10 countries (end‑2024), and supplied patient recruitment ~40% from advocacy networks; orphan\/fast‑track interactions lower timeline risk and affect launch revenue timing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUPenn GTP\u003c\/td\u003e\n\u003ctd\u003eAAV platform\/IP\u003c\/td\u003e\n\u003ctd\u003e$24M saved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eVector production\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% production (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eTrials\u003c\/td\u003e\n\u003ctd\u003e~40 sites, 10 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy\u003c\/td\u003e\n\u003ctd\u003eRecruitment\u003c\/td\u003e\n\u003ctd\u003e~40% enrollments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Passage Bio detailing customer segments, value propositions, channels, revenue streams, key partners, activities, resources, cost structure and governance tailored to its gene therapy strategy, with SWOT-linked insights and investor-ready narrative for presentations and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise one-page Business Model Canvas for Passage Bio that highlights therapeutic value propositions, patient and payer segments, and scalable R\u0026amp;D partnerships—editable for quick strategy alignment and board-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and manage Phase 1\/2 and planned Phase 3 trials for lead asset PBFT02, selecting ~20–30 global sites and enrolling patients with biallelic PAH mutations; monitor safety and efficacy over multi-year follow‑up to capture durability and AAV-related events.\u003c\/p\u003e\n\u003cp\u003eAnalyze interim and final datasets (target n≈60–120 per pivotal trial), generate statistical reports to support BLA filing, and track clinical spend—Passage Bio reported $72.3M R\u0026amp;D spend in 2024—while minimizing dropout to protect power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenetic Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio invests \u0026gt;$150M in R\u0026amp;D annually (2024 report) to ID and validate genetic targets for rare CNS disorders, optimize transgenes, and select AAV capsids for brain\/spinal delivery.\u003c\/p\u003e\n\u003cp\u003eOngoing vector-design innovation—reducing off-target expression by \u0026gt;30% in preclinical tests—drives pipeline expansion into new indications and underpins clinical-stage programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Strategy and Filing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManaging INDs, CTAs, and rolling submissions is a daily task—team prepares investigational new drug applications, answers regulator queries on trial protocols, and files orphan, RMAT and fast track requests to cut review time; PassageBio reported $158m R\u0026amp;D spend in 2024 supporting these activities. Strategic regulatory planning targets shortening development timelines by 20–30% through special designations and proactive agency engagement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Oversight and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManufacturing oversight ensures each gene therapy batch meets exact specs, with PassageBio monitoring partners to keep viral titer and purity consistent—critical after their 2024 CMC investments of $45M to scale GMP capacity.\u003c\/p\u003e\n\u003cp\u003eRobust QC systems prevent contamination and potency loss, supporting regulatory approvals and patient safety; industry failure rates for biologics batch release average 2–5% so tight controls cut recall risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMonitor viral titer, purity, potency\u003c\/li\u003e\n\u003cli\u003eImplement GMP-grade QC assays\u003c\/li\u003e\n\u003cli\u003eAudit CMOs regularly\u003c\/li\u003e\n\u003cli\u003eTrack batch failure rates (target \u0026lt;2%)\u003c\/li\u003e\n\u003cli\u003eAllocate capital for CMC scale-up ($45M in 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Financial Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePassage Bio must actively manage capital to fund costly gene-therapy trials, combining investor relations, equity\/debt raises, and tight budgeting to extend runway to key readouts; as of Q3 2025 the company reported cash and equivalents of about $320M, covering near-term milestones but requiring strategic raises for late-stage programs.\u003c\/p\u003e\n\u003cp\u003eFinancial strategists monitor market windows to time offerings and reallocate resources so highest-probability programs get prioritized funding for pivotal data events.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ3 2025 cash ≈ $320M\u003c\/li\u003e\n\u003cli\u003ePrioritize programs with highest clinical probability\u003c\/li\u003e\n\u003cli\u003eUse equity\/debt timing based on market signals\u003c\/li\u003e\n\u003cli\u003eBudget to extend runway to next readouts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase 1\/2→3 PBFT02 trials, $72M R\u0026amp;D \u0026amp; $45M CMC; runway to Q3 2025 ~$320M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesign\/manage PBFT02 Phase 1\/2→3 trials (20–30 sites; n≈60–120), analyze datasets for BLA, oversee CMC\/GMP scale-up ($45M 2024), control R\u0026amp;D spend ($72.3M 2024; $158M total cited), and manage cash runway (Q3 2025 cash ≈ $320M) via fundraising and priority-based budgeting.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites\u003c\/td\u003e\n\u003ctd\u003e20–30\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlanned n\u003c\/td\u003e\n\u003ctd\u003e60–120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend 2024\u003c\/td\u003e\n\u003ctd\u003e$72.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMC 2024\u003c\/td\u003e\n\u003ctd\u003e$45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 cash\u003c\/td\u003e\n\u003ctd\u003e$320M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Passage Bio Business Model Canvas—not a mockup or sample—and reflects the same content and layout you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll get this exact file in its full form, ready to download, edit, present, and share with no hidden sections or altered formatting.\u003c\/p\u003e\n\u003cp\u003eWe provide full transparency: the preview equals the final deliverable, so what you see here is precisely what you’ll own upon purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749872546169,"sku":"passagebio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/passagebio-business-model-canvas.png?v=1772219557","url":"https:\/\/matrixbcg.com\/products\/passagebio-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}